chlorzoxazone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
626 95-25-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorzoxazone
  • 5-Chlorobenzoxazolidone
  • chlorzoxazon
  • chloroxazone
A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
  • Molecular weight: 169.56
  • Formula: C7H4ClNO2
  • CLOGP: 1.87
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 38.33
  • ALOGS: -1.76
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.25 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 196.38 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Aug. 15, 1958 FDA JANSSEN R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional overdose 108.18 23.07 48 1628 74104 63413242
Intentional self-injury 108.05 23.07 36 1640 25651 63461695
Completed suicide 48.68 23.07 36 1640 145637 63341709
Stress cardiomyopathy 34.77 23.07 12 1664 9438 63477908
Toxicity to various agents 34.00 23.07 37 1639 247213 63240133
Pulmonary renal syndrome 31.32 23.07 6 1670 448 63486898
Depressed level of consciousness 29.29 23.07 19 1657 62059 63425287
Stevens-Johnson syndrome 26.48 23.07 13 1663 24937 63462409
Anti-neutrophil cytoplasmic antibody positive vasculitis 24.70 23.07 7 1669 2892 63484454
Loss of consciousness 24.21 23.07 22 1654 118099 63369247

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Secondary adrenocortical insufficiency 84.27 42.28 14 291 1456 34955170
Spinal column injury 50.45 42.28 8 297 616 34956010

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional self-injury 89.63 24.80 31 1574 32388 79710395
Intentional overdose 88.82 24.80 43 1562 105917 79636866
Secondary adrenocortical insufficiency 62.30 24.80 14 1591 3000 79739783
Completed suicide 48.94 24.80 40 1565 245727 79497056
Stress cardiomyopathy 36.00 24.80 12 1593 11154 79731629
Spinal column injury 33.65 24.80 8 1597 2190 79740593
Pulmonary renal syndrome 30.89 24.80 6 1599 634 79742149
Loss of consciousness 30.59 24.80 26 1579 167917 79574866
Sensory disturbance 28.83 24.80 11 1594 15066 79727717
Toxicity to various agents 27.74 24.80 38 1567 421502 79321281
Dizziness 26.75 24.80 42 1563 526399 79216384
Anti-neutrophil cytoplasmic antibody positive vasculitis 24.84 24.80 7 1598 3722 79739061

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M03BB03 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
ATC M03BB53 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
ATC M03BB73 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:51371 muscle relaxants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018373 Peripheral Nervous System Agents
FDA PE N0000175730 Centrally-mediated Muscle Relaxation
FDA EPC N0000175737 Muscle Relaxant

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Spasticity indication 221360009
Muscle Spasm with Pain indication
Alcoholism contraindication 7200002
Hepatic failure contraindication 59927004
Poisoning by acetaminophen contraindication 70273001
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.22 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Calcium-activated potassium channel subunit alpha-1 Ion channel OPENER EC50 4.52 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Intermediate conductance calcium-activated potassium channel protein 4 Ion channel ACTIVATOR EC50 4 IUPHAR
Nitric oxide synthase, brain Enzyme IC50 4.30 CHEMBL
Nitric oxide synthase, inducible Enzyme IC50 4.85 CHEMBL
Nitric oxide synthase, endothelial Enzyme IC50 5.06 CHEMBL
Nitric oxide synthase, brain Enzyme IC50 5.55 DRUG MATRIX
Small conductance calcium-activated potassium channel protein 2 Ion channel ACTIVATOR EC50 4.10 IUPHAR

External reference:

IDSource
4017882 VUID
N0000146235 NUI
D00771 KEGG_DRUG
2410 RXNORM
4017882 VANDF
C0008296 UMLSCUI
CHEBI:3655 CHEBI
CLW PDB_CHEM_ID
CHEMBL1371 ChEMBL_ID
DB00356 DRUGBANK_ID
D002753 MESH_DESCRIPTOR_UI
2733 PUBCHEM_CID
748 INN_ID
2322 IUPHAR_LIGAND_ID
H0DE420U8G UNII
4369 MMSL
4433 MMSL
d00962 MMSL
001671 NDDF
400361007 SNOMEDCT_US
44908000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 0254-2005 TABLET 750 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 0254-2053 TABLET 375 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2520 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2520 TABLET 500 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 13811-717 TABLET 375 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 13811-717 TABLET 375 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 13811-718 TABLET 750 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 13811-718 TABLET 750 mg ORAL ANDA 12 sections
CHLORZOXAZONE Human Prescription Drug Label 1 16571-725 TABLET 375 mg ORAL ANDA 11 sections
CHLORZOXAZONE Human Prescription Drug Label 1 16571-725 TABLET 375 mg ORAL ANDA 11 sections
CHLORZOXAZONE Human Prescription Drug Label 1 16571-726 TABLET 500 mg ORAL ANDA 11 sections
CHLORZOXAZONE Human Prescription Drug Label 1 16571-726 TABLET 500 mg ORAL ANDA 11 sections
CHLORZOXAZONE Human Prescription Drug Label 1 16571-727 TABLET 750 mg ORAL ANDA 11 sections
CHLORZOXAZONE Human Prescription Drug Label 1 16571-727 TABLET 750 mg ORAL ANDA 11 sections
CHLORZOXAZONE HUMAN PRESCRIPTION DRUG LABEL 1 16590-478 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 21695-569 TABLET 500 mg ORAL ANDA 12 sections
CHLORZOXAZONE HUMAN PRESCRIPTION DRUG LABEL 1 24470-923 TABLET 250 mg ORAL ANDA 12 sections
CHLORZOXAZONE HUMAN PRESCRIPTION DRUG LABEL 1 24470-923 TABLET 250 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 33261-021 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42254-076 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-425 TABLET 375 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-426 TABLET 500 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-427 TABLET 500 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-428 TABLET 750 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 45865-434 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 49999-044 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 50090-0315 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 50090-0315 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 50090-0316 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 51862-338 TABLET 375 mg ORAL ANDA 14 sections